# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT02998112 (Continued)

# Inclusion criteria

- History of safety using 5-ASA
- Ability to undergo endoscopy examination
- Ages 18–65 years

# Exclusion criteria

- Use of immunosuppressive drugs and glucocorticoids within 4 weeks
- Use of antibiotics within 7 days
- High risk of toxic megacolon
- Colon cancer or neoplasia
- Other severe diseases (e.g. cardiovascular, respiratory, gastrointestinal, and kidney)

# Interventions

# Experimental arm

- 5-ASA 4 g/day enema through TET for 1 week; 200 mL FMT suspension infusion through TET for 3 doses every other day for 1 week

# Control arm

- 5-ASA 4 g/day enema through TET for 1 week; 200 mL saline infusion through TET for 3 doses every other day for 1 week

# Outcomes

# Primary outcomes

- Clinical remission at week 12: Total Mayo score < 2 and no signal item > 1
- Clinical improvement at week 12: Total Mayo score decreased > 3 or > 30%

# Secondary outcomes

- Change in intestinal microbiota composition after FMT at week 12: compared with participant's original microbiota and donor microbiota

# Starting date

December 2016

# Contact information

Faming Zhang

Associate professor, Gastroenterology, The Second Hospital of Nanjing Medical University, China

# Notes

Estimated enrollment: 188

# NCT03078803

# Study name

Fecal transplant for Crohn's disease

# Methods

Multicenter RCT conducted in Canada

# Participants

# Inclusion criteria

- Age ≥ 18 years
- Mild-to-moderate ileal, ileo-colonic, or colonic CD
- Active ileal or colonic (or both) disease on endoscopy with/without elevated inflammatory markers, i.e. CRP > 8 mg/L, fecal calprotectin > 250 μg/g
- If applicable, medications on stable dose: 5-ASA for 4 weeks, prednisone ≤ 20 mg once daily for 4 weeks, budesonide ≤ 6 mg once daily for 4 weeks, azathioprine, 6-mercaptopurine and methotrexate for 12 weeks

# Exclusion criteria

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.